GlassScriptPhysician profile
David Moshe Yashar
NPI 1396205316
$8,152.04
in general payments reported to CMS, 2019-2025
45 companies · $4,012 in 2025
The $4,012 reported for 2025 was more than what 79% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $14.16 · 2022: $373 · 2023: $1,431 · 2024: $2,321 · 2025: $4,012.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,567 · Consulting Fee: $675 · Education: $522.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,567.48 |
| Consulting Fee | $675.00 |
| Education | $521.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,716.03 | 2024-2025 | Rybrevant, Carvykti, Tecvayli |
| Astrazeneca Pharmaceuticals LP | $1,068.15 | 2023-2025 | Imfinzi, Tagrisso, Calquence |
| E.R. Squibb & Sons, L.L.C. | $451.31 | 2020-2025 | Reblozyl, Opdualag, Opdivo |
| Genzyme Corporation | $392.02 | 2023-2025 | |
| Pfizer INC. | $329.76 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $292.57 | 2022 | |
| Celgene Corporation | $281.98 | 2022-2025 | Reblozyl, Pomalyst |
| Emd Serono, INC. | $278.76 | 2023-2025 | Bavencio |
| Alexion Pharmaceuticals, INC. | $259.52 | 2023-2025 | Soliris, Ultomiris |
| Merck Sharp & Dohme LLC | $253.90 | 2025 | Keytruda, Welireg, Keytruda Qlex |
| Gilead Sciences, INC. | $230.85 | 2023-2025 | Trodelvy |
| Incyte Corporation | $225.10 | 2025 | Jakafi, Monjuvi, Zynyz |
| Beone Medicines USA, INC. | $192.15 | 2025 | Tevimbra, Brukinsa |
| Geron Corporation | $170.74 | 2025 | Rytelo |
| Genmab U.S., INC. | $158.68 | 2023-2024 | Epkinly |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Yashar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.